Is the overall survival for older adults with AML finally improving?

被引：29
作者：
Lancet, Jeffrey E. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, 12902 Magnolia Dr, Tampa, FL 33612 USA
来源：
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2018年 / 31卷 / 04期
关键词：
Acute myeloid leukemia; AML; CPX-351; Elderly; Glasdegib; Hypomethylating; Intensive; Survival; Venetoclax; ACUTE MYELOID-LEUKEMIA; LOW-DOSE CYTARABINE; TIPIFARNIB; INHIBITOR; REGIMENS; PHASE-3; TRIAL; CARE;
D O I：
10.1016/j.beha.2018.09.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Older adults with acute myeloid leukemia (AML) traditionally have very poor survival outcomes. Those who receive only supportive care have worse overall survival than those who undergo treatment, regardless of treatment type, and improvements in overall survival in the last several decades are largely attributable to the increasing decision to treat rather than offer only supportive care. However, there are a few newer agents that appear promising; these include CPX-351 (a liposomal product with cytarabine and daunorubicin), glasdegib (a selective Hedgehog signaling pathway inhibitor), and venetoclax (potent small molecule inhibitor of BCL2). A systematic review and meta-analysis is being completed to help clinicians optimize standard therapies for older AML patients.
引用
收藏
页码：387 / 390
页数：4
相关论文
共 18 条
  • [1] A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia
    Burnett, A. K.
    Russell, N.
    Hills, R. K.
    Panoskaltsis, N.
    Khwaja, A.
    Hemmaway, C.
    Cahalin, P.
    Clark, R. E.
    Milligan, D.
    [J]. LEUKEMIA, 2015, 29 (06) : 1312 - 1319
  • [2] Therapeutic Advances in Acute Myeloid Leukemia
    Burnett, Alan
    Wetzler, Meir
    Loewenberg, Bob
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : 487 - 494
  • [3] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    Burnett, Alan K.
    Milligan, Donald
    Prentice, Archie G.
    Goldstone, Anthony H.
    McMullin, Mary F.
    Hills, Robert K.
    Wheatley, Keith
    [J]. CANCER, 2007, 109 (06) : 1114 - 1124
  • [4] The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML
    Burnett, Alan K.
    Russell, Nigel H.
    Culligan, Dominic
    Cavanagh, Jamie
    Kell, Jonathan
    Wheatley, Keith
    Virchis, Andra
    Hills, Robert K.
    Milligan, Donald
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) : 519 - 522
  • [5] Cortes J. E., 2016, BLOOD, V128
  • [6] Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
    Doehner, Hartmut
    Luebbert, Michael
    Fiedler, Walter
    Fouillard, Loic
    Haaland, Alf
    Brandwein, Joseph M.
    Lepretre, Stephane
    Reman, Oumedaly
    Turlure, Pascal
    Ottmann, Oliver G.
    Mueller-Tidow, Carsten
    Kraemer, Alwin
    Raffoux, Emmanuel
    Doehner, Konstanze
    Schlenk, Richard F.
    Voss, Florian
    Taube, Tillmann
    Fritsch, Holger
    Maertens, Johan
    [J]. BLOOD, 2014, 124 (09) : 1426 - 1433
  • [7] International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
    Dombret, Herve
    Seymour, John F.
    Butrym, Aleksandra
    Wierzbowska, Agnieszka
    Selleslag, Dominik
    Jang, Jun Ho
    Kumar, Rajat
    Cavenagh, James
    Schuh, Andre C.
    Candoni, Anna
    Recher, Christian
    Sandhu, Irwindeep
    Bernal del Castillo, Teresa
    Al-Ali, Haifa Kathrin
    Martinelli, Giovanni
    Falantes, Jose
    Noppeney, Richard
    Stone, Richard M.
    Minden, Mark D.
    McIntyre, Heidi
    Songer, Steve
    Lucy, Lela M.
    Beach, C. L.
    Doehner, Hartmut
    [J]. BLOOD, 2015, 126 (03) : 291 - 299
  • [8] Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432
    Erba, Harry P.
    Othus, Megan
    Walter, Roland B.
    Kirschbaum, Mark H.
    Tallman, Martin S.
    Larson, Richard A.
    Slovak, Marilyn L.
    Kopecky, Kenneth J.
    Gundacker, Holly M.
    Appelbaum, Frederick R.
    [J]. LEUKEMIA RESEARCH, 2014, 38 (03) : 329 - 333
  • [9] Extermann M, 2016, J GERIATR ONCOL S1, V7, pS27
  • [10] A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
    Harousseau, Jean-Luc
    Martinelli, Giovanni
    Jedrzejczak, Wieslaw W.
    Brandwein, Joseph M.
    Bordessoule, Dominique
    Masszi, Tamas
    Ossenkoppele, Gert J.
    Alexeeva, Julia A.
    Beutel, Gernot
    Maertens, Johan
    Vidriales, Maria-Belen
    Dombret, Herve
    Thomas, Xavier
    Burnett, Alan K.
    Robak, Tadeusz
    Khuageva, Nuriet K.
    Golenkov, Anatoly K.
    Tothova, Elena
    Mollgard, Lars
    Park, Youn C.
    Bessems, Annick
    De Porre, Peter
    Howes, Angela J.
    [J]. BLOOD, 2009, 114 (06) : 1166 - 1173
12